Somewhat Favorable News Coverage Somewhat Unlikely to Affect Valeritas (VLRX) Stock Price
News stories about Valeritas (NASDAQ:VLRX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Valeritas earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.1101791288082 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Valeritas (NASDAQ:VLRX) traded down $0.33 on Thursday, hitting $4.25. The company’s stock had a trading volume of 41,700 shares, compared to its average volume of 31,044. Valeritas has a 1 year low of $2.00 and a 1 year high of $48.00. The company has a debt-to-equity ratio of 3.54, a quick ratio of 3.20 and a current ratio of 3.88.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Valeritas (VLRX) Stock Price” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/30/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-valeritas-vlrx-stock-price.html.
Valeritas Company Profile
Valeritas, Inc is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin.
Receive News & Ratings for Valeritas Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.